医学
血脂异常
疾病
他汀类
死因
人口
冲程(发动机)
糖尿病
内科学
环境卫生
机械工程
工程类
内分泌学
作者
Carol M. Mangione,Michael J. Barry,Wanda K. Nicholson,Michael D. Cabana,David Chelmow,Tumaini R. Coker,Esa M. Davis,Katrina E Donahue,Carlos Roberto Jaén,Martha Kubik,Li Li,Gbenga Ogedegbe,Lori Pbert,John Ruiz,James Stevermer,John B. Wong
出处
期刊:JAMA
[American Medical Association]
日期:2022-08-23
卷期号:328 (8): 746-746
被引量:301
标识
DOI:10.1001/jama.2022.13044
摘要
The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year CVD risk of 10% or greater. (B recommendation) The USPSTF recommends that clinicians selectively offer a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more of these CVD risk factors and an estimated 10-year CVD risk of 7.5% to less than 10%. The likelihood of benefit is smaller in this group than in persons with a 10-year risk of 10% or greater. (C recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating a statin for the primary prevention of CVD events and mortality in adults 76 years or older. (I statement).
科研通智能强力驱动
Strongly Powered by AbleSci AI